OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Tumor microenvironment as a therapeutic target in cancer	628
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections	347
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	263
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development	228
Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?	212
Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders	212
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients	208
The birth of artemisinin	159
The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species	158
Resolution of inflammation: An organizing principle in biology and medicine	143
Advances in pathogenesis and therapeutic strategies for osteoporosis	137
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions	136
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression	135
TRPC channels: Structure, function, regulation and recent advances in small molecular probes	128
Therapeutic targets in lung tissue remodelling and fibrosis	109
Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans	109
Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics	108
Programming inflammatory cell death for therapy	107
Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective	105
Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment	103
The strategies and techniques of drug discovery from natural products	100
Carcinogenesis: Failure of resolution of inflammation?	99
Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential	97
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint	96
Therapeutic potential of resveratrol against emerging respiratory viral infections	95

Physiologically-based pharmacokinetic models for children: Starting to reach maturation?	90
Traditional application and modern pharmacological research of Artemisia annua L.	89
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases	87
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	87
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	85
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders	83
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders	81
Targeting the NLRP3 inflammasome in cardiovascular diseases	80
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy	79
Role of the ERO1-PDI interaction in oxidative protein folding and disease	79
Chinmedomics, a new strategy for evaluating the therapeutic efficacy of herbal medicines	78
Bile acid metabolism and signaling, the microbiota, and metabolic disease	76
Role of inflammatory chemokines in hypertension	76
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms	76
Evidence-based pharmacological treatment options for ADHD in children and adolescents	76
Polyphenols and neuroprotection: Therapeutic implications for cognitive decline	73
Kynurenine emerges from the shadows – Current knowledge on its fate and function	71
Biased GPCR signaling: Possible mechanisms and inherent limitations	71
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma	71
Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies	69
A decade of cell death studies: Breathing new life into necroptosis	68
Current developments of targeting the p53 signaling pathway for cancer treatment	68
The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention	68
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	67
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy	67
Updates on community acquired pneumonia management in the ICU	65
Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis	65
The Role of non-coding RNAs in colorectal cancer, with a focus on its autophagy	65
Circular RNAs are a novel type of non-coding RNAs in ROS regulation, cardiovascular metabolic inflammations and cancers	62
Tumor organoid models in precision medicine and investigating cancer-stromal interactions	62
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options	62
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges	62
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases	61
Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors	61
Stepping forward in antibody-drug conjugate development	60
Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain	60